BeiGene Reports Results of Tislelizumab in P-III (RATIONALE 306) Trial as 1L Treatment of Advanced Esophageal Squamous Cell Carcinoma
Shots:
- The P-III (RATIONALE 306) trial evaluates tislelizumab + CT vs PBO + CT in a ratio (1:1) in 649 patients with advanced or metastatic ESCC across Asia-Pacific, EU & North America
- The study had met its 1EPs of OS in patients with prior untreated advanced or metastatic ESCC. The safety & tolerability profile was consistent with previous trials with no new safety signals
- Tislelizumab is currently under the US FDA & EMA’s review for advanced or metastatic ESCC. The EMA also reviews tislelizumab for advanced or metastatic NSCLC after prior CT. In Jan 2021, BeiGene collaborated with Novartis to accelerate the clinical development and marketing of tislelizumab in North America, the EU, and Japan
Ref: Businesswire | Image: BeiGene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
